UAE experience with teprotumumab in treatment of thyroid eye disease – cases series
Author: Habibullah Eatamadi
Base Hospital / Institution: Sheikh Shakhbout Medical City
ePoster presentation
Abstract ID: 24-118
Purpose
To report our experience with the use of Teprotumumab in treatment of thyroid eye disease (TED).
Methods
This is a retrospective case series. Eight patients were treated with intravenous infusions of the IGF-IR inhibitor teprotumumab (10 mg per kilogram for the first infusion and 20 mg per kilogram for subsequent infusions) once every 3 weeks for 21 weeks starting in May 2023. The cases consisted of heterogenous group of patients. They had different degrees of severity and activity of TED. Two cases had inactive thyroid eye disease and treatment was given to reduce their proptosis. Two patients had previously been treated with either/or intravenous steroid and/or Tocilizumab and/or orbital wall decompression who relapsed. 5 patients (one of which had inactive TED). All of the patients completed the course of treatment. The primary outcome was a proptosis response (a reduction in proptosis of ≥2.5 mm) at week 24. Secondary outcomes included reduction in Clinical Activity Score, improvement in diplopia and improvement in quality of life. All patient had baseline audiometry testing prior to treatment as well as the following tests: Full blood count, Liver function test, kidney function test, thyroid function test, including antibodies.
Results
Seven out of eight patients responded positively to the treatment in primary outcome i.e reduction of proptosis by at least 2.5mm. All active TED cases (6 patients) had improvement of clinical activity score by at least 3 scores. Double vision improved completely in 1 patient and improved in 2 more patients. Seven patients reported improvement in QOL. One patient with inactive TED responded partially to treatment. the other inactive TED case responded fully to the treatment (proptosis reduction of 3 mm). Side effects were minor and included temporary derangement of blood glucose control, pruritus and dry skin, and muscle cramps.
Conclusion
Teprotumumab seems to be a promising treatment for active thyroid eye disease. To our knowledge this is the first reported experience in the Middle East. More longterm data is needed to fully understand the effectiveness of this novel treatment
Additional Authors
| First name | Last name | Base Hospital / Institution |
|---|---|---|
| Ohood | Almazrouie | Sheikh Shakhbout Medical City |
| Noora | Alqattan | Sheikh Shakhbout Medical City |
